Condition

OCD

ClinicalTrials.gov condition label

Clinical trials8

Recruiting2

Common interventions10

Lead sponsors shown7

Clinical trials

8 shown

Open-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · 2024-10-17

Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health TrajectoriesNCT06978452 · 2024-07-01

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · 2024-12-12

Testing a Transdiagnostic TMS Treatment TargetNCT06282146 · 2024-09-09

Psychiatric Orders in Psychoanalytic Treatment of ASDNCT05930912 · 2023-06-01

Role of Basal Ganglia and Thalamus in Perceptual Consciousness and MetacognitionNCT04461730 · 2021-12-01

DELPhI Evaluation of Psychiatric ConditionsNCT03842345 · 2020-03-01

Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label StudyNCT00708396 · 2008-07-01

Common interventions

Cognitive Behavioral TherapyBEHAVIORAL1 deep brain stimulationDEVICE1 Duloxetine 20 MGDRUG1 EscitalopramDRUG1 PlaceboDRUG1 PsilocybinDRUG1 PsychoanalysisDIAGNOSTIC_TEST1 Serotonergic PsychedelicDRUG1 sertraline 50mgDRUG1 transcranial magnetic stimulationPROCEDURE1

Leading sponsors

Yale University2 BeerYaakov Mental Health Center1 Brigham and Women's Hospital1 Douglas Mental Health University Institute1 QuantalX Neuroscience1 University Hospital, Grenoble1 Yang I. Pachankis, PhD1

Trial status mix

RECRUITING2

UNKNOWN2

WITHDRAWN2

COMPLETED1

TERMINATED1

Phase mix

EARLY_PHASE11

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.